
New GLP-1 Analog Catalog Line — 50 Ready-to-Ship SKUs
Responding to surging demand in the metabolic disease space, we have launched 50 new GLP-1 receptor agonist analogs available for immediate dispatch in research and GMP grades.
Priority Sales Hotline
WhatsApp to inquire

Company News
Product launches, capacity expansions, and partnerships.

Responding to surging demand in the metabolic disease space, we have launched 50 new GLP-1 receptor agonist analogs available for immediate dispatch in research and GMP grades.

Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%.

AODT Peptide has entered a multi-year exclusive supply agreement for three oncology peptide APIs with a leading European pharmaceutical company, valued at over $45M.
We use cookies
We use essential cookies to make our site work, and optional analytics & preference cookies to improve your experience. See our Cookie Policy.